Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. - Wikidata - wikimedia - TriplyDB

Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.

Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.

http://www.wikidata.org/entity/Q37869274

about

Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis Guidelines for therapeutic drug monitoring of vancomycin: a systematic review Achieving therapeutic vancomycin levels in pediatric patients Anti-infective use in children and pregnancy: current deficiencies and future challenges.An evaluation of initial vancomycin dosing in infants, children, and adolescents.Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling.Improved vancomycin dosing in children using area under the curve exposure.A Prospective Study to Assess Vancomycin Serum Concentrations inPediatric Patients with Current Dosing Guidelines.The effect of age and weight on vancomycin serum trough concentrations in pediatric patients.Assessment of therapeutic drug monitoring of vancomycin in elderly patients according to new guidelines.Vancomycin dosing in children: what is the question?Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Factors associated with acute kidney injury in children receiving vancomycin.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.Pediatric Assessment of Vancomycin Empiric Dosing (PAVED): a Retrospective Review.Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis.Evaluation of Vancomycin Dosing in Pediatric Cystic Fibrosis Patients.Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?Assessment of initial vancomycin dosing in neonates Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population.Vancomycin use, dosing and serum trough concentrations in the pediatric population: a retrospective institutional review.Are Elevated Vancomycin Serum Trough Concentrations Achieved Within the First 7 Days of Therapy Associated With Acute Kidney Injury in Children?Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin.Late-Occurring Vancomycin-Associated Acute Kidney Injury in Children Receiving Prolonged Therapy.Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study.Endothelial, renal and hepatic variables in Wistar rats treated with Vancomycin.Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.Prediction of Vancomycin Dose for Recommended Trough Concentrations in Pediatric Patients With Cystic Fibrosis.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.Vancomycin trough concentrations in overweight or obese pediatric patients.What do I need to know about glycopeptide antibiotics?Use of Individual Pharmacokinetics to Improve Time to Therapeutic Vancomycin Trough in Pediatric Oncology Patients.Factors affecting serum concentration of vancomycin in critically ill oliguric pediatric patients receiving continuous venovenous hemodiafiltration.

P2860

Q28534516-A6035705-7530-4BB3-9346-16EA1C5F750A Q28539717-729E3BC4-0A30-49FB-B331-77B4BB719426 Q34764337-36C465AD-3345-477F-94B1-CFE114EB4AFA Q35023696-240BDFD7-6A07-4EF2-A7E2-E98D0D0CAC42 Q35419960-D7CFFB76-66A0-48AB-A5B3-DDBE47133A9D Q36571794-C3860BC0-1755-4E2A-8537-34387040EB2D Q36784672-5C545479-7876-4114-B273-DD33C9FDC6E1 Q37178123-DAAB8321-01C7-451E-BEDF-9AB306DE8ACC Q37347361-E5DB7662-7CA2-4900-B7FB-7D0BC68D94FA Q37453459-E69B6710-A8B4-4FF5-B449-BC6B6A0B4C5B Q38129843-B98B53BE-CFB6-4C80-99A4-30FA1AED0615 Q38215682-9CC84A9B-F8CF-4DF7-B1C3-0E8C777E398F Q38245931-AF21907D-B625-4035-A74C-72C584074D50 Q38258649-4E7F8FEB-DB6F-45FF-834B-099167EFF813 Q38392526-0F2EC5CA-AA5B-4889-9569-12C1DAC16423 Q38641774-82518B25-E9AB-4361-892D-6F564E141834 Q38839166-561E5450-35B8-4C59-BC64-50FC920D60D5 Q39044128-50CDFB86-5E54-4CF8-9FFF-32062A67F391 Q39110114-BFB9DCB4-816E-403B-AD35-293E5BA15846 Q39197603-FBE1E22A-4548-4B83-A90C-DDB1C8166BE6 Q39424620-7378036A-A08F-4056-A585-8B4289ECEC7C Q40254585-CF7827E7-BC3B-4145-B9CB-F60264A3FFEF Q40441139-EC9F805C-1532-48E7-B70F-218B1DE539A7 Q41115090-FC1D8325-1A08-491A-BE17-0ABAA0E0C639 Q41255520-2FA34FC2-9EF5-4F06-99FB-BE0C478A1409 Q41543583-49C005EE-D442-40A2-98B4-E3189A836E92 Q43984406-5FB71293-F87D-4D22-8D95-62A2828DE261 Q47565991-6344B096-D3ED-436D-A88E-359F93EF7962 Q48197188-0E043A75-435A-4B5F-9E30-CB7CCB3B1455 Q51195290-DBBF22F4-9BDC-4DB6-B7A2-4475C242DFB1 Q54559172-8FFD81B5-4E90-42E2-9D4E-1A14ED22554C Q55136102-8FAA6590-1100-4CD3-9204-1BA1419CE5F9 Q55463665-B02F11AC-F75D-498D-8129-6E7AA85BA318

P2860

Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.

http://www.wikidata.org/entity/Q37869274

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Assessment of vancomycin dosin ...... rations in pediatric patients.

@en

Assessment of vancomycin dosin ...... rations in pediatric patients.

@nl

type

label

Assessment of vancomycin dosin ...... rations in pediatric patients.

@en

Assessment of vancomycin dosin ...... rations in pediatric patients.

@nl

prefLabel

Assessment of vancomycin dosin ...... rations in pediatric patients.

@en

Assessment of vancomycin dosin ...... rations in pediatric patients.

@nl

P1433

Q37869274-D2A2E510-8AD7-46A8-BF79-A5ABCFFA4140

P1476

Q37869274-7B1268CF-406C-4212-AE44-18991D20E46B

P2093

Q37869274-094C46D1-0938-494C-ADDC-4AC8AD27714F

Q37869274-843FFD67-D97B-46D7-89CE-182DBAC19527

Q37869274-B1AF38A9-D50E-4BB9-8B9C-183847AF7909

P2860

Q37869274-225B6445-A987-4931-8C8C-8D57587710F4

Q37869274-6B79F379-1AD9-4BB9-BD08-9BD6D7F486A7

Q37869274-6E7D3BA6-BD4B-4589-84A0-AA2590F6E065

Q37869274-7735C650-47C4-483C-9A34-A7F209B4EE87

Q37869274-9CA8EC13-5A8E-46AE-A4A8-0DF77513769C

Q37869274-A755D43F-C0C7-4E62-9930-9B8C15F658CD

Q37869274-ACE66AF2-E331-45D1-9829-85FFFD918E47

Q37869274-F1ADD246-B244-4C92-8FED-B8C401FEBD70

Q37869274-F9C94388-D5CF-4D51-B81D-03CFAC5790A9

P304

Q37869274-9B8FBDBF-291D-4DA0-8777-312D2C305AE3

P31

Q37869274-122FE960-CE47-4003-8A5C-2D6C98175154

P356

Q37869274-8B525328-1D0A-422B-BB09-BAF230CA8991

P407

Q37869274-C816525A-9C4B-43B6-B7B5-2F0F7C2C77D5

P433

Q37869274-9BEA92EC-03B0-4F18-8589-CD9C47E3BF53

P478

Q37869274-91908879-B3CB-4EF3-868B-B8A6897CA574

P577

Q37869274-8A544713-BDAF-4D59-9DF4-4CF874BD70C1

P698

Q37869274-83532198-9D53-431F-954F-D77097B54AF5

P356

P1433

Annals of Pharmacotherapy

P1476

Assessment of vancomycin dosin ...... rations in pediatric patients.

@en

P2093

Edward H Eiland

http://www.w3.org/2001/XMLSchema#string

Lea S Eiland

http://www.w3.org/2001/XMLSchema#string

Thomas M English

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.

Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Special considerations for monitoring vancomycin concentrations in pediatric patients.

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Initial vancomycin dosing in pediatric oncology and stem cell transplant patients.

Clinical pharmacology and efficacy of vancomycin in pediatric patients.

P304

582-589

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1P588

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21521865

http://www.w3.org/2001/XMLSchema#string